62 related articles for article (PubMed ID: 19462760)
1. [Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma].
Takita J; Ogawa S
Tanpakushitsu Kakusan Koso; 2009 May; 54(6):742-7. PubMed ID: 19462760
[No Abstract] [Full Text] [Related]
2. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
3. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
4. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
5. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
6. All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.
Futami H; Sakai R
Cancer Lett; 2010 Nov; 297(2):220-5. PubMed ID: 20576349
[TBL] [Abstract][Full Text] [Related]
7. [ALK, a key gene in the pathogenesis of neuroblastoma].
Janoueix-Lerosey I; Delattre O
Med Sci (Paris); 2009 Apr; 25(4):330-2. PubMed ID: 19409178
[No Abstract] [Full Text] [Related]
8. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
9. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
Carén H; Abel F; Kogner P; Martinsson T
Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
[TBL] [Abstract][Full Text] [Related]
10. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
Mathivet T; Mazot P; Vigny M
Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
[TBL] [Abstract][Full Text] [Related]
12. Genetics and genomics of neuroblastoma.
Capasso M; Diskin SJ
Cancer Treat Res; 2010; 155():65-84. PubMed ID: 20517688
[TBL] [Abstract][Full Text] [Related]
13. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
14. [Discovery of a gene mutation associated with familial neuroblastoma].
Nau JY
Rev Med Suisse; 2008 Sep; 4(169):1888. PubMed ID: 18831412
[No Abstract] [Full Text] [Related]
15. Inhibitors of protein kinases induce differentiation in human neuroblastoma cell lines.
Rocchi P; Ferreri AM; Simone G; Magrini E; Cavallazzi L; Paolucci G
Anticancer Res; 1995; 15(4):1381-5. PubMed ID: 7654025
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
17. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ALK signaling for cancer therapy.
Mossé YP; Wood A; Maris JM
Clin Cancer Res; 2009 Sep; 15(18):5609-14. PubMed ID: 19737948
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of peripheral neuroblastic tumors.
Janoueix-Lerosey I; Schleiermacher G; Delattre O
Oncogene; 2010 Mar; 29(11):1566-79. PubMed ID: 20101209
[TBL] [Abstract][Full Text] [Related]
20. Patterns of regulation of nuclear proto-oncogenes MYCN and MYB in retinoic acid treated neuroblastoma cells.
Thiele CJ
Prog Clin Biol Res; 1991; 366():151-6. PubMed ID: 2068135
[No Abstract] [Full Text] [Related]
[Next] [New Search]
